Expanding the Genetic Architecture of Nicotine Dependence and its Shared Genetics with Multiple Traits: Findings from the Nicotine Dependence GenOmics (iNDiGO) Consortium
Bryan C. Quach,
Michael J Bray,
Nathan C. Gaddis,
Camelia C. Minica,
Kendra A. Young,
Jesse A. Marks,
Megan U. Carnes,
Nancy Y.A. Sey,
Maria T Landi,
Daniel W. McNeil,
Lindsay A. Farrer,
Christina A Markunas,
Jacqueline M. Vink,
William G Iacono,
Henry R. Kranzler,
Nancy L. Saccone,
Michael C. Neale,
Marcella D.C. Rietschel,
Mary L. Marazita,
Georg Winterer and the German Nicotine Cohort Study,
Richard A. Grucza,
Danielle M Dick,
Neil E. Caporaso,
Timothy B. Baker,
Dorret I. Boomsma,
jaakko a kaprio,
John E Hokanson,
Laura J. Bierut,
Eric O. Johnson,
Dana B. Hancock
Posted 15 Jan 2020
bioRxiv DOI: 10.1101/2020.01.15.898858
Posted 15 Jan 2020
Cigarette smoking is the leading cause of preventable morbidity and mortality. Knowledge is evolving on genetics underlying initiation, regular smoking, nicotine dependence (ND), and cessation. We performed a genome-wide association study using the Fagerström Test for ND (FTND) in 58,000 smokers of European or African ancestry. Five genome-wide significant loci, including two novel loci MAGI2/GNAI1 (rs2714700) and TENM2 (rs1862416) were identified, and loci reported for other smoking traits were extended to ND. Using the heaviness of smoking index (HSI) in the UK Biobank (N=33,791), rs2714700 was consistently associated, but rs1862416 was not associated, likely reflecting ND features not captured by the HSI. Both variants were cis-eQTLs (rs2714700 for MAGI2-AS3 in hippocampus, rs1862416 for TENM2 in lung), and expression of genes spanning ND-associated variants was enriched in cerebellum. SNP-based heritability of ND was 8.6%, and ND was genetically correlated with 17 other smoking traits (rg=0.40-0.95) and co-morbidities. Our results emphasize the FTND as a composite phenotype that expands genetic knowledge of smoking, including loci specific to ND. ### Competing Interest Statement L.J.B. and the spouse of N.L.S. are listed as inventors on U.S. Patent 8,080,371, 'Markers for Addiction' covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Y.G. is an employee of GeneCentric Therapeutics. Although unrelated to this research, H.R.K. is an advisory board member for Dicerna and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor and Amygdala Neurosciences. H.R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. J.K. consulted for Pfizer in 2012-2015 on ND. All other authors declare no conflict of interest.
- Downloaded 507 times
- Download rankings, all-time:
- Site-wide: 42,820 out of 118,373
- In genomics: 3,560 out of 6,435
- Year to date:
- Site-wide: 13,781 out of 118,373
- Since beginning of last month:
- Site-wide: 24,724 out of 118,373
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!